Keyvan Rezaï
Impact in
- Hematology top 2%
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Molecular Biology top 5%
- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
- Ubiquitin and proteasome pathways
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
Papers in
-
- Protein Degradation and Inhibitors 20
- Histone Deacetylase Inhibitors Research 6
- DNA Repair Mechanisms 3
- Oncology 24
- HER2/EGFR in Cancer Research 8
- Cancer Treatment and Pharmacology 5
- Co-authors
- François Lokiec (43 shared papers)Patrice Herait (11 shared papers)Mohamed Békradda (8 shared papers)Carmen Kahatt (5 shared papers)Anastasios Stathis (8 shared papers)María E. Riveiro (10 shared papers)Esteban Cvitkovic (11 shared papers)Elodie Odore (9 shared papers)
- Journals
- Cancer Research (10 papers)Journal of Clinical Oncology (8 papers)European Journal of Cancer (5 papers)Cancer Chemotherapy and Pharmacology (4 papers)Oncotarget (3 papers)
- Partner nations
- FranceUnited StatesSwitzerland
In The Last Decade
Keyvan Rezaï
68 papers receiving 1.9k citations
Peers
Comparison fields: 5 of 88
- Hematology 544
- Molecular Biology 1.4k
- Oncology 401
- Genetics 88
- Cancer Research 93
Countries citing papers authored by Keyvan Rezaï
This map shows the geographic impact of Keyvan Rezaï's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keyvan Rezaï with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keyvan Rezaï more than expected).
Fields of papers citing papers by Keyvan Rezaï
This network shows the impact of papers produced by Keyvan Rezaï. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keyvan Rezaï. The network helps show where Keyvan Rezaï may publish in the future.
Co-authors
The 25 scholars most cited alongside Keyvan Rezaï, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 70 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 342 | |
| 2 | 2016 | 335 | |
| 3 | 2018 | 209 | |
| 4 | 2016 | 124 | |
| 5 | 2016 | 82 | |
| 6 | 2015 | 73 | |
| 7 | 2016 | 50 | |
| 8 | 2017 | 47 | |
| 9 | 2013 | 44 | |
| 10 | 2012 | 39 | |
| 11 | 2021 | 28 | |
| 12 | 2010 | 28 | |
| 13 | 2005 | 28 | |
| 14 | 2015 | 26 | |
| 15 | 2018 | 24 | |
| 16 | 2016 | 23 | |
| 17 | 2016 | 23 | |
| 18 | 2018 | 21 | |
| 19 | 2011 | 18 | |
| 20 | 2021 | 18 |
About Keyvan Rezaï
Keyvan Rezaï is a scholar working on Molecular Biology, Oncology, Hematology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 70 papers that have together received 1.9k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (20 papers), Multiple Myeloma Research and Treatments (11 papers), HER2/EGFR in Cancer Research (8 papers), Histone Deacetylase Inhibitors Research (6 papers), Cancer Treatment and Pharmacology (5 papers), Microtubule and mitosis dynamics (4 papers), Chronic Lymphocytic Leukemia Research (4 papers) and DNA Repair Mechanisms (3 papers). The work is most often cited by research in Hematology (544 citations), Molecular Biology (1.4k citations), Oncology (401 citations), Genetics (88 citations) and Cancer Research (93 citations). Keyvan Rezaï has collaborated with scholars based in France, United States and Switzerland. Frequent co-authors include François Lokiec, Patrice Herait, Mohamed Békradda, Carmen Kahatt, Anastasios Stathis, María E. Riveiro, Esteban Cvitkovic, Elodie Odore, Bruno Quesnel and Catherine Thiéblemont. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, European Journal of Cancer, Cancer Chemotherapy and Pharmacology and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.